Medical/Pharmaceuticals
Zhendong Pharmaceutical Announces Publication of Phase IIb Study of Investigational Vaginal Lactobacillus Capsule in the National Medical Journal of China
BEIJING, Sept. 30, 2026 /PRNewswire/ -- Zhendong Pharmaceutical
2026-09-30 20:00
1466
EASD 2026 | Ecnoglutide Demonstrates Favorable Safety Profile in Adolescents with Obesity
HANGZHOU, China, Sept. 30, 2026 /PRNewswire/ -- At the 62nd Annual Meeting of the European Association for the Study of Diabetes (EASD), Hangzhou Sciwind Biosciences Co., Ltd. ("Sciwind") today announced that its Phase 1b randomized, double-blind, placebo-controlled study of ecnoglutide, the worl...
2026-09-30 19:00
3030
Rznomics Receives Positive Opinion for Orphan Medicinal Product Designation of RZ-001 for Glioma
SEONGNAM, South Korea, Sept. 30, 2026 /PRNewswire/ -- Rznomics Inc., a biopharmaceutical company specializing in the development of RNA-based gene therapies, announced that the European Medicines Agency's (EMA) Committee for Orphan Medicinal Products (COMP) adopted a positive opinion on the Orpha...
2026-09-30 17:33
1277
Breaking the Safety Barrier: Insilico Medicine Nominates ISM1354, the Next-Generation Small Molecule GIPR Antagonist
CAMBRIDGE, Mass., Sept. 30, 2026 /PRNewswire/ -- As population aging accelerates with demand for weight management continuing to expand, the market for GLP-1 receptor agonist (GLP-1RA) drugs is experiencing explosive growth. Tirzepatide, with annual sales of $36.507 billion in 2025, has become th...
2026-09-30 13:57
1444
Ontario Contributes $1.7 Million Investment to Advance Life Sciences Innovation at Piramal Pharma's Aurora Facility
* Piramal Pharma Solutions is investing over $5.3 million in its Aurora drug substance facility to upgrade site infrastructure. * With its investment through the Life Sciences Scale-Up Fund, the Ontario government is supporting healthcare innovation and reinforcing its province's leadership p...
2026-09-30 03:28
3159
2026 International Day of Older Persons: Dimora Medical Supports Dignified Longevity with Advanced Home Wound Care
NEW YORK, Sept. 29, 2026 /PRNewswire/ -- As the world observes the 2026 United
Nations International Day of Older Persons under the theme "The Age of
Longevity: Rethinking Systems for Longer Lives
2026-09-30 01:50
2511
Yuyu Teijin Medicare Uses Drones to Deliver Medical Supplies to Patients on Korea's Remote Islands
SEOUL, South Korea, Sept. 29, 2026 /PRNewswire/ -- Yuyu Teijin Medicare, a home healthcare joint venture between Yuyu Pharma of Korea and Teijin Pharma of Japan, has completed a pilot delivery of medical supplies by drone to a ventilator patient living on a remote Korean island. In the test, a d...
2026-09-29 21:00
2287
Elsevier launches ClinicalKey Nursing AI, a new evidenced-based clinical AI solution built specifically for nurses
Developed to fit around nursing workflows, ClinicalKey Nursing AI gives nurses fast, traceable answers to clinical questions at the point of care. NEW YORK, Sept. 29, 2026 /PRNewswire/ -- Today Elsevier announced the global launch of ClinicalKey Nursing AI, the clinical AI tool built specifically...
2026-09-29 20:00
2744
iRegene Therapeutics's NouvSight001 Cleared for Clinical Trials in the U.S. and China for Retinitis Pigmentosa
- Following its Parkinson's disease program, iRegene advances another off-the-shelf cell therapy into clinical development in the U.S. and China. CHENGDU, China, Sept. 29, 2026 /PRNewswire/ -- iRegene Therapeutics Co., Ltd. ("iRegene" or the "Company"), a biotechnology company pioneering chemical...
2026-09-29 13:41
2091
Hengrui Pharma and Novo Enter Exclusive License Agreement for Once-Weekly Oral GLP-1/GIP Dual Receptor Agonist HRS-1596
* HRS-1596 is a phase I-ready GLP-1/GIP dual receptor agonist for once-weekly oral dosing * Total potential deal value is up to 2.6 billion US dollars, including 300 million dollars upfront, as well as potential sales royalties SHANGHAI, Sept. 29, 2026 /PRNewswire/ -- Hengrui Pharm...
2026-09-29 13:12
2350
Open-Source Model Accelerates Global Progress in Medical Video AI
SHANGHAI, Sept. 28, 2026 /PRNewswire/ -- Through an open-source model, a public dataset and benchmark, and the MedVidU Challenge, a global research competition, researchers worldwide now share a common foundation for advancing medical video AI. The Challenge drew 75 teams from 18 countries and re...
2026-09-28 21:19
3686
Lunit Expands AI-Powered Breast Cancer Screening Across the Stockholm Region
Following years of clinical validation and proven real-world performance at Saint Göran, Stockholm Region adopts Lunit INSIGHT MMG as an independent second reader at regional scale SEOUL, South Korea, Sept. 28, 2026 /PRNewswire/ -- Lunit (KRX:328130), a leading provider of AI for cancer diagnost...
2026-09-28 21:00
2575
Jaypirca® (pirtobrutinib) Approved in China for a New Indication in Chronic Lymphocytic Leukemia (CLL) /Small Lymphocytic Lymphoma (SLL) Across All Lines of Therapy
SAN FRANCISCO and SUZHOU, China, Sept. 28, 2026 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and commercializes high-quality medicines for the treatment of oncology, autoimmune, cardiovascular and metabol...
2026-09-28 18:30
2561
111, Inc. Announces Establishment of the Special Committee
SHANGHAI, Sept. 28, 2026 /PRNewswire/ -- 111, Inc. ( "111" or the "Company") (NASDAQ: YI), a leading tech-enabled healthcare platform company in China, announced today that the special committee (the "Special Committee"), comprising of three independent directors, Mr. Jian Sun, who is the chairma...
2026-09-28 16:30
4014
SOLA Biosciences Japan Receives AMED Grant to Advance SOL-257, Innovative Gene Therapy Aiming to Restore TDP-43 Function for ALS Patients
TOKYO and BOSTON, Sept. 28, 2026 /PRNewswire/ -- SOLA Biosciences Japan GK ("SOLA Japan"), the wholly owned Japanese subsidiary of Boston-based SOLA Biosciences Inc. (together, "SOLA"), announced that it has been awarded a grant of approximately 6 billion yen over five years by the Japan Agency f...
2026-09-28 14:00
2666
Akeso Announces First Patient Enrolled in Global Phase III Trial of Cadonilimab Versus Nivolumab in First-Line Gastric Cancer
HONG KONG, Sep. 27, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") today announced that the first patient has been enrolled in COMPASSION-37 (AK104-311), a global, multicenter Phase III head-to-head trial evaluating cadonilimab, Akeso's first-in-class PD-1/CTLA-4 bispecific...
2026-09-28 10:05
3892
Innovent Announces Expansion of Global Phase 3 MarsLight-11 Study of IBI363/TAK-928 (Alpha-biased IL-2/PD-1 Bispecific Fusion Protein) in Immunotherapy-Resistant NSCLC to Include Patients with Non-Squamous NSCLC
SAN FRANCISCO and SUZHOU, China, Sept. 27, 2026 /PRNewswire/ -- Innovent Biologics, Inc. (HKEX Stock Code: 01801), a biopharmaceutical company dedicated to the research, development, manufacturing, and commercialization of innovative drugs for major diseases including oncology, autoimmune, metabo...
2026-09-28 08:00
2784
2026 IMS | IASO Bio Presented FUCASO China Real-World Data
--- In a large China real-world study of 281 heavily pretreated, predominantly high-risk patients with relapsed/refractory plasma cell neoplasms,FUCASO achieved a 95.9% objective response rate, a 77.2% CR/sCR rate, and a 94.1% MRD negativity rate --- with median PFS and OS not yet reached (12-mo...
2026-09-27 11:16
2936
2026 IMS | IASO Bio Presented First-in-Human Data of BCMA-Targeted In Vivo CAR-T Cell Therapy IASO206
— Late-breaking oral presentation of first-in-human data (LBA-11) showed that a single intravenous infusion of IASO206 generated functional BCMA CAR-T cells in vivo without lymphodepleting chemotherapy. The study demonstrated a 90% objective response rate and a 90% MRD negativity rate in a popula...
2026-09-27 11:03
8344
Second NRF2 Degrader Enters Clinical Development: Nutshell Therapeutics' NTS231 Received FDA IND Clearance
SHANGHAI, Sept. 25, 2026 /PRNewswire/ -- Nutshell Therapeutics (Shanghai) Co., Ltd. ("Nutshell Therapeutics"), an innovative biotech company focused on AI-driven allosteric drug discovery, announced FDA IND clearance for NTS231, a covalent allosteric molecular glue degrader of NRF2, to launch cli...
2026-09-25 20:00
9989
Week's Top Stories
Most Reposted
HLB Customers Can Now Scan & Pay in China with HLB QR Pay
[Picked up by 294 media titles]
2026-10-22 22:35
SALMON SECURES $140 MILLION (PHP 8.8 BILLION) TO DOUBLE DOWN ON THE GROWTH OPPORTUNITY IN THE PHILIPPINES
[Picked up by 283 media titles]
2026-10-19 13:18
Infobip and Yamaha Power Conversational Customer Engagement in Indonesia's Automotive Sector
[Picked up by 276 media titles]
2026-10-21 15:00
TCL Zhonghuan Powers India's Energy Transition with PV Innovations at REI Expo 2026
[Picked up by 275 media titles]
2026-10-23 21:52
DayOne Supports NVIDIA DSX POD Reference Design, Advancing Standardized Infrastructure for AI
[Picked up by 271 media titles]
2026-10-22 11:55Most Read
Hi3D V1.0 Goes Open Source: The First Production-Validated Open-Source AI 3D Model
2026-10-23 23:30
24286
Home 3D Printers are More Accessible Than Ever This Black Friday with Bambu Lab
2026-10-22 17:00
21040
BeautyPlus Web Launches Halloween Photo Booth With Behind-the-Scenes Video Export
2026-10-23 01:00
19072
Cuttable Unveils Next-Generation AI Advertising Platform as U.S. Expansion Accelerates
2026-10-24 00:00
17552